scholarly journals Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Panagiotis I. Georgianos ◽  
Vasilios Vaios ◽  
Eleni Leontaridou ◽  
Georgia Karayannopoulou ◽  
Triantafyllia Koletsa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Interstitial Nephritis ◽  
Cell Lung Cancer ◽  
Acute Interstitial Nephritis ◽  
Small Cell ◽  
Close Monitoring ◽  
Partial Recovery ◽  
Small Cell Lung

Immune-checkpoint-inhibitors (ICPIs) represent a novel class of immunotherapy against several malignancies. These agents are associated with several “immune-mediated” adverse effects, but the reported renal toxicity of ICPIs is less well defined. We present the case of a 60-year-old man with a history of non-small cell lung cancer, who developed acute kidney injury (AKI) approximately 3.5 months after initiation of immunotherapy with nivolumab. Urinalysis revealed sterile pyuria, without microscopic hematuria or proteinuria. Immunological examination was negative. A renal biopsy showed severe interstitial inflammatory infiltration of T-cells, monocytes, and eosinophils without interstitial granulomas and normal appearance of glomeruli, indicating acute interstitial nephritis (AIN) as the cause of AKI. After a short-term course of corticosteroids and permanent nivolumab discontinuation, partial recovery of renal function was noted. AIN is a rare adverse effect of ICPIs that mandates the close monitoring of renal function in patients under immunotherapy with these agents.

Effects of brain irradiation and chemotherapy on myelosuppression in small-cell lung cancer.

1986 ◽  
Vol 4 (11) ◽  
pp. 1615-1619 ◽  
Author(s):  
J S Lee ◽  
T Umsawasdi ◽  
H M Dhingra ◽  
H T Barkley ◽  
W K Murphy
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Infectious Complications ◽  
Small Cell ◽  
Close Monitoring ◽  
Small Cell Lung ◽  
Brain Irradiation ◽  
Chemotherapy Dose ◽  
Dose Reductions

The effect of brain irradiation on myelosuppression was studied in patients with untreated small-cell lung cancer (SCLC) by comparing 24 patients who received brain irradiation for brain metastasis at presentation (irradiated patients) with 24 control patients who were selected by matching ages and non-CNS metastatic sites with those of irradiated patients. All patients were evaluated during the first three courses of chemotherapy. More irradiated patients than control patients had chemotherapy dose reductions from the starting dose level for the second (nine of 22 v two of 24; P = .03) and the third (nine of 18 v three of 20; P = .05) courses of chemotherapy. Overall, more irradiated patients had chemotherapy dose reductions than did control patients (11 of 22 v three of 24; P = .01). The difference was highly significant even after other variables were considered in a multivariate analysis (P less than .001). Myelosuppression was more severe in irradiated patients for WBCs (P = .01) and for platelets (P = .05). When the second course of chemotherapy was administered at the same dose levels as in the first course, irradiated patients had greater decreases in nadir counts after the second course compared with the first course than did control patients. Irradiated patients had a higher incidence of infectious complications than did control patients (14 of 24 v six of 24; P = .02), particularly after the second course of chemotherapy (seven of 22 v one of 24; P = .04). There were four treatment-related deaths due to sepsis in irradiated patients. Following brain irradiation given concurrently with intensive chemotherapy, close monitoring of myelosuppression and adjustments of chemotherapy doses are advised.

Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed

2020 ◽  
Vol 76 (11) ◽  
pp. 1573-1580
Author(s):  
Louis Magali ◽  
Foucher Pascal ◽  
Aho Serge ◽  
Boulin Mathieu ◽  
Zouak Ayoube ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Impaired Renal Function ◽  
Small Cell ◽  
Small Cell Lung

Effects of Gemcitabine on renal function in patients with non-small cell lung cancer

1998 ◽  
Vol 34 (1) ◽  
pp. 199-202 ◽  
Author(s):  
J.A Gietema ◽  
H.J.M Groen ◽  
S Meijer ◽  
E.F Smit
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non–small‐cell lung cancer: A retrospective cohort study (HYCIS‐XL)

2020 ◽  
Vol 45 (5) ◽  
pp. 1153-1158 ◽  
Author(s):  
Kelly L. Niggebrugge‐Mentink ◽  
Marieke M. Beex‐Oosterhuis ◽  
Peter G. J. Horst ◽  
Matthijs E. C. Poll ◽  
Hetty G. Dieleman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Cohort Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Small Cell ◽  
Small Cell Lung

Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer

2016 ◽  
Vol 37 (4) ◽  
pp. 363-373 ◽  
Author(s):  
Weiwei Tan ◽  
Shinji Yamazaki ◽  
Theodore R. Johnson ◽  
Rong Wang ◽  
Melissa T. O’Gorman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive ◽  
Dose Recommendations

Interstitial nephritis with pembrolizumab: A case report and review

2020 ◽  
pp. 107815522096155
Author(s):  
A Peláez Bejarano ◽  
O Montero Pérez ◽  
A Inoriza Rueda ◽  
MT Garrido Martínez
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Kidney Function ◽  
Interstitial Nephritis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Total Recovery ◽  
Common Causes

Introduction Pembrolizumab is a monoclonal antibody approved for adult patients with advanced non–small-cell lung cancer (NSCLC). Although immune related adverse events are considered to be well tolerated, complications may occur and discontinuation of the treatment could be required. Case report A 62-year old patient diagnosed with advanced non-small cell lung cancer experienced a decline in the renal function after seven cycles with pembrolizumab. Management & outcome: After ruling out other common causes of interstitial nephritis, pembrolizumab was attributed as a cause of interstitial nephritis. At first, toxicity was managed with corticosteroids and closely monitoring the patient, but finally pembrolizumab had to be discontinued due to the kidney function did not recover. Discussion Renal and urinary disorders were reported in <3% of patients treated with pembrolizumab, being interstitial nephritis the most reported toxicity. The kidney damage can be a complication to consider in patients receiving pembrolizumab. Early identification of an increase in serum creatinine levels may help with prevention by establishing an effective treatment, although it may not mean a total recovery of kidney function.

Sign in / Sign up

Export Citation Format

Share Document